Fast Dissociating Dopamine D2 Antagonists for Schizophrenia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antipsychotic medications for schizophrenia often cause motor side effects and metabolic disorders due to slow dissociation from dopamine D2 receptors and non-selective receptor interactions.
Innovation Solution
Development of fast dissociating dopamine D2 receptor antagonists with a selective profile, represented by compounds of Formula (I), which have a rapid dissociation rate from dopamine D2 receptors and minimal interaction with other receptors, reducing the risk of motor side effects and metabolic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antipsychotic medications are used to treat schizophrenia, then antipsychotic efficacy is achieved, but motor side effects and metabolic disorders occur due to slow dissociation from dopamine D2 receptors and non-selective receptor interactions
Solution Approach 1:
The patent applies parameter changes by modifying the dissociation rate parameter of dopamine D2 receptor antagonists. The compounds are designed to dissociate rapidly (fast dissociation) from the D2 receptor, which is a fundamental parameter change compared to conventional antipsychotics. This parameter change resolves the contradiction by maintaining antipsychotic efficacy while reducing motor side effects and metabolic disorders associated with slow-dissociating agents
Solution Approach 2:
The patent applies local quality by achieving selective receptor interaction - the compounds exhibit high affinity and selectivity for dopamine D2 receptors while having minimal interaction with other receptor types. This localized specificity at the D2 receptor site allows the drug to produce therapeutic effects without the non-selective receptor interactions that cause metabolic side effects
2Object-affected harmful factors
If fast dissociating dopamine D2 receptor antagonists are used, then motor side effects are reduced, but maintaining antipsychotic efficacy becomes challenging
Solution Approach 1:
The patent optimizes the dissociation rate parameter to achieve fast dissociation from D2 receptors while maintaining sufficient binding affinity to ensure antipsychotic efficacy. The compounds are designed with specific molecular structures that enable rapid unbinding from the receptor, reducing motor side effects, while the high affinity ensures adequate occupancy to maintain therapeutic effect
3Object-affected harmful factors
If selective D2 receptor antagonists are used, then metabolic disorders are reduced, but the ability to treat all symptoms of schizophrenia may be limited
Solution Approach 1:
The patent applies local quality through highly selective D2 receptor interaction, where the compounds specifically target dopamine D2 receptors with minimal off-target activity. This selective mechanism reduces metabolic disorders caused by non-selective receptor binding while the high affinity and fast dissociation properties ensure effective treatment of positive schizophrenia symptoms through dopaminergic pathways
Data Source
AI summary
The present invention relates to compounds that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds of the invention can be administered to a patient in need thereof to treat or prevent psychosis including, but not limited to, schizophrenia, schizophreniform disorder and schizoaffective disorder. Compounds of the present invention include those encompassed by Formula I.